



## PRESS RELEASE

---

### ASLAN PHARMACEUTICALS HOSTS ONCOLOGY SYMPOSIUM FOR INVESTORS

**Taipei, Taiwan, 26 September 2017** – ASLAN Pharmaceuticals (ASLAN, 6497.TT), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, will host an investor symposium in Taipei, Taiwan titled ‘Understanding Oncology for Investors’ tomorrow, 27 September 2017.

Organised in partnership with Bernstein Research, KGI Securities, Taiwan Liposome Company (TLC), JHL Biotech and the Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), the symposium is targeted at investors who are interested in oncology, with an aim to help improve their understanding of this complex domain. The symposium is aimed at generalist investors, as well as first time biotech investors.

Leading clinicians and industry veterans speaking at symposium include:

- Hong Jen Chang, Chairman, TRPMA;
- Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals;
- Dr Laura Nelson Carney, Senior Research Analyst, Bernstein Research;
- Professor Tsu-Yi Chao, Chair and Professor of Haematology and Oncology at Shuang-Ho Hospital, Taipei Medical University;
- Professor Hui-Chuan Sun, Deputy Head, Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University;
- Dr Yao-Yu Hsieh, Attending Physician of Haematology and Oncology at Shuang-Ho Hospital, Taipei Medical University; and
- Dr Chih-Yi Hsieh, Vice President (Medical) and General Manager (Taiwan), ASLAN Pharmaceuticals.

No company information will be shared at this event.

**ENDS**

#### Media contacts

**Chris Fang**

ASLAN Pharmaceuticals

Tel: +886 2 2758 3333

E-mail: [media@aslanpharma.com](mailto:media@aslanpharma.com)

**Emma Thompson / Stephanie Tan**

Spurwing Communications

Tel: +65 6340 7287

Email: [ASLAN@spurwingcomms.com](mailto:ASLAN@spurwingcomms.com)

#### About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (6497.TT) is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform that reaches across the region via its offices in Taiwan, China and Australia. The Company is developing 5 drugs addressing multiple indications including biliary tract cancer, gastric cancer and colorectal cancer, and has two global pivotal studies in biliary tract cancer and gastric cancer underway. ASLAN’s partners include Array BioPharma, Bristol-Myers Squibb, Ammirall and CSL. [www.aslanpharma.com](http://www.aslanpharma.com)



**Cautionary statement**

*All materials and information set out herein are for reference only and whilst we make every effort to ensure accuracy and completeness, we cannot guarantee this. We make no recommendation as to the competence or suitability of persons or entities referenced herein (if any). Nothing herein constitutes an invitation or offer to invest in or deal in the securities of ASLAN. Anyone considering investment in ASLAN should refer to the information officially published the Taiwan Stock Exchange Market Observation System (MOPS). All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on such forward-looking statements, which are inherently unreliable, and you should not rely on them. Any such forward-looking statement will have been based on ASLAN's expectations, assumptions, estimates and projections about future events on the date(s) made. Actual outcomes are subject to numerous risks and uncertainties, many of which relate to factors beyond ASLAN's control, that could cause them to differ materially from those expressed in a forward-looking statement. ASLAN has no obligation to update or otherwise revise any forward-looking statements to reflect the occurrence of unanticipated events or for any other reason.*